Bacteraemic urinary tract infections in a tertiary hospital in Japan: the epidemiology of community-acquired infections and the role of non-carbapenem therapy

Table 4 Studies on the effectiveness of non-carbapenem versus carbapenem treatment for UTIs due to ESBL-producing organisms

No	Author, year	Country	Enrolment criteria	Source of infection	Study design	Non-CBP agents	Compared therapy	Pathogen	Outcome	Result
#1	Paterson, 2004	Seven countries^a	BSI	UTI 14%	Prospective	Any	DT	KP	28-day mortality	CBP was superior
#2	Lee, 2010	Taiwan	BSI	UTI 7.4%	Retrospective	BL	DT	Enterobacter cloacae	Mortality	CBP was superior
#3	Rodriguez-Bano, 2012	Spain	BSI	UTI and biliary tract infection 70%	Post-hoc analysis	BLBLI	ET, DT	EC	Mortality	NS
#4	Doi, 2013	Japan	Bacteriuria	Only UTI	Retrospective	CMZ	Through ET and DT	Any	Clinical and microbiological cure	NS
#5	Kelvin, 2013	China	BSI	UTI 44%	Retrospective	Any	ET, DT	EC	30-day mortality	NS
#6	Park, 2014	Korea	Pyelonephritis	Only UTI	Retrospective	Any	Through ET and DT	EC	Clinical failure	NS
#7	Tamma, 2015	US	BSI	UTI 19%	Retrospective	PT	ET	Any	14-day mortality	CBP was superior
#8	Harris, 2015	Singapore	BSI	UTI 47%	Retrospective	BLBLI	DT	EC and KP	30-day mortality	NS
#9	Matsumura, 2015	Japan	BSI	UTI 45%	Retrospective	CMZ, FMOX	ET, DT	EC	30-day mortality, clinical response	NS
#10	Lee, 2015	Taiwan	BSI	UTI 23%	Retrospective	FMOX	DT	EC and KP	30-day mortality	CBP was superior
#11	Tsai, 2015	Taiwan	BSI	UTI 51%	Retrospective	PT	DT	Proteus mirabilis	30-day mortality	NS

UTIs, urinary tract infections; ESBL, extended-spectrum beta-lactamase; CBP, carbapenem; BSI, blood stream infection; DT, definitive therapy; KP, Klebsiella pneumoniae; BL, β-lactam; BLBLI, β-lactam with β-lactamase inhibitor; ET, empiric therapy; EC, Escherichia coli; NS, non-significant difference; CMZ, cefmetazole; FMOX, flomoxef; PT, piperacillin/tazobactam
^aSouth Africa, Taiwan, Australia, Argentina, US, Belgium, and Turkey

ISSN: 1756-0500